» Articles » PMID: 25006259

Covalent Agonists for Studying G Protein-coupled Receptor Activation

Overview
Specialty Science
Date 2014 Jul 10
PMID 25006259
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Structural studies on G protein-coupled receptors (GPCRs) provide important insights into the architecture and function of these important drug targets. However, the crystallization of GPCRs in active states is particularly challenging, requiring the formation of stable and conformationally homogeneous ligand-receptor complexes. Native hormones, neurotransmitters, and synthetic agonists that bind with low affinity are ineffective at stabilizing an active state for crystallogenesis. To promote structural studies on the pharmacologically highly relevant class of aminergic GPCRs, we here present the development of covalently binding molecular tools activating Gs-, Gi-, and Gq-coupled receptors. The covalent agonists are derived from the monoamine neurotransmitters noradrenaline, dopamine, serotonin, and histamine, and they were accessed using a general and versatile synthetic strategy. We demonstrate that the tool compounds presented herein display an efficient covalent binding mode and that the respective covalent ligand-receptor complexes activate G proteins comparable to the natural neurotransmitters. A crystal structure of the β2-adrenoreceptor in complex with a covalent noradrenaline analog and a conformationally selective antibody (nanobody) verified that these agonists can be used to facilitate crystallogenesis.

Citing Articles

G Protein-Coupled Receptor-Ligand Pose and Functional Class Prediction.

Szwabowski G, Griffing M, Mugabe E, OMalley D, Baker L, Baker D Int J Mol Sci. 2024; 25(13).

PMID: 38999982 PMC: 11241240. DOI: 10.3390/ijms25136876.


Technologies for Direct Detection of Covalent Protein-Drug Adducts.

Mons E, Kim R, Mulder M Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111304 PMC: 10146396. DOI: 10.3390/ph16040547.


Homology Modeling of the G Protein-Coupled Receptors.

Mordalski S, Kosciolek T Methods Mol Biol. 2023; 2627:167-181.

PMID: 36959447 DOI: 10.1007/978-1-0716-2974-1_9.


Photochromic Fentanyl Derivatives for Controlled μ-Opioid Receptor Activation.

Lahmy R, Hubner H, Schmidt M, Lachmann D, Gmeiner P, Konig B Chemistry. 2022; 28(63):e202201515.

PMID: 35899620 PMC: 9826449. DOI: 10.1002/chem.202201515.


New Chemical Biology Tools for the Histamine Receptor Family.

Zheng Y, Wagner G, Hauwert N, Ma X, Vischer H, Leurs R Curr Top Behav Neurosci. 2022; 59:3-28.

PMID: 35851442 DOI: 10.1007/7854_2022_360.


References
1.
Nijmeijer S, Engelhardt H, Schultes S, van de Stolpe A, Lusink V, de Graaf C . Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor. Br J Pharmacol. 2013; 170(1):89-100. PMC: 3764852. DOI: 10.1111/bph.12113. View

2.
Zou Y, Weis W, Kobilka B . N-terminal T4 lysozyme fusion facilitates crystallization of a G protein coupled receptor. PLoS One. 2012; 7(10):e46039. PMC: 3464249. DOI: 10.1371/journal.pone.0046039. View

3.
Westfield G, Rasmussen S, Su M, Dutta S, DeVree B, Chung K . Structural flexibility of the G alpha s alpha-helical domain in the beta2-adrenoceptor Gs complex. Proc Natl Acad Sci U S A. 2011; 108(38):16086-91. PMC: 3179071. DOI: 10.1073/pnas.1113645108. View

4.
Caffrey M, Cherezov V . Crystallizing membrane proteins using lipidic mesophases. Nat Protoc. 2009; 4(5):706-31. PMC: 2732203. DOI: 10.1038/nprot.2009.31. View

5.
Kobilka B . Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal Biochem. 1995; 231(1):269-71. DOI: 10.1006/abio.1995.1533. View